Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multiple strengths. The ...

The uptick in Zydus Life share price came after the company announced that it has received final approval from the USFDA to ...

Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Ph+, chronic myeloid leukemia ...

The pharma company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture ...

Zydus Lifesciences added 3.33% to Rs 917.10 after the company said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture generic Dasatinib ...

Zydus Lifesciences Ltd on Wednesday (March 5) said it has received final approval from the United States Food and Drug ...

IT services company TCS has collaborated with Vantage Towers, Europe’s second-largest telecom tower operator, to introduce a ...

Dasatinib is prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults.

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) ...

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin (DQ), ...

With annual US sales of $1.81 billion, as per IQVIA MAT data (January 2025), this approval marks a significant milestone for Zydus. The company will manufacture Dasatinib at its Ahmedabad SEZ facility ...